Balance Sheet
Cash Flow Statement
AmortizationOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Cash from Investing Activities (2016 - 2022)

Historic Cash from Investing Activities for RedHill Biopharma (RDHL) over the last 11 years, with Q3 2022 value amounting to -$22000.0.

  • RedHill Biopharma's Cash from Investing Activities rose 9974.18% to -$22000.0 in Q3 2022 from the same period last year, while for Dec 2022 it was $8.3 million, marking a year-over-year increase of 20199.02%. This contributed to the annual value of -$9000.0 for FY2024, which is 32500.0% down from last year.
  • Latest data reveals that RedHill Biopharma reported Cash from Investing Activities of -$22000.0 as of Q3 2022, which was up 9974.18% from -$163000.0 recorded in Q2 2022.
  • RedHill Biopharma's Cash from Investing Activities' 5-year high stood at $11.7 million during Q3 2019, with a 5-year trough of -$49.8 million in Q2 2020.
  • Moreover, its 5-year median value for Cash from Investing Activities was $387000.0 (2021), whereas its average is -$1.4 million.
  • Per our database at Business Quant, RedHill Biopharma's Cash from Investing Activities crashed by 289771.43% in 2019 and then skyrocketed by 209302.33% in 2022.
  • RedHill Biopharma's Cash from Investing Activities (Quarter) stood at $175000.0 in 2018, then plummeted by 2897.71% to -$4.9 million in 2019, then surged by 260.36% to $7.9 million in 2020, then plummeted by 55.46% to $3.5 million in 2021, then plummeted by 100.63% to -$22000.0 in 2022.
  • Its last three reported values are -$22000.0 in Q3 2022, -$163000.0 for Q2 2022, and $8.5 million during Q1 2022.